Dr. Stefanie Schlager
Post-doc
Dr. Stefanie Schlager
Post-doc – Biomarker and Translational Research
PhD in Metabolic and Cardiovascular Disease, Medical University Graz (Austria)
Project
Evaluate a new therapeutic treatment option by a novel class of BCL6 compounds, which not only lead to inhibition but also degradation of BCL6. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of B cell lymphoma. The transcription factor BCL6 is a known oncogene in DLBCL that represses gene transcription through the recruitment of co-repressor proteins via its BTB domain. The BTB domain of Bcl6 has been shown to be highly druggable by small molecule inhibitors.
Publications
Kerres N, Steurer S, Schlager S, Bader G, Berger H, Caligiuri M et al (2017). Chemically induced degradation of the oncogenic transcription factor BCL6. Cell Rep (12):2860-2875.
Schlager S, Salomon, S, Olt, S, Albrecht C, Ebert, A et al (2019). Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis MCR: submitted
Supervisor
Dr. Vittoria Zinzalla
Scientific Director – Pharmacology and Translational Research – Cancer Research
PhD in Cell Biology, University of Milano-Bicocca (Italy)
Research interests:
- Biomarker discovery with focus on cancer cell directed and immunotherapies in early stage drug development
- Genomics, molecular biology, experimental pathology
- Oncology drug discovery